SPS
VIR icon

Susquehanna Portfolio Strategies’s Vir Biotechnology VIR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Sell
345,541
-8,122
-2% -$77.3K 0.06% 352
2026
Q1 		$3.17M Buy
353,663
+306,231
+646% +$2.44M 0.05% 397
2025
Q4 		$286K Hold
47,432
– – ﹤0.01% 893
2025
Q3 		$271K Hold
47,432
– – ﹤0.01% 936
2025
Q2 		$239K Buy
+47,432
New +$254K 0.01% 780

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Susquehanna Portfolio Strategies's VIR Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its Vir Biotechnology (VIR) stake by 2.3% in Q2 2026, selling an estimated $77.3K and leaving 345,541 shares worth $3.52M. The position accounts for 0.06% of the portfolio, ranked #352.

Susquehanna Portfolio Strategies first reported a position in VIR in Q2 2025 and has held it in 5 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Susquehanna Portfolio Strategies held 345,541 shares of Vir Biotechnology worth $3.52M as of Q2 2026.
  • Susquehanna Portfolio Strategies sold 8,122 Vir Biotechnology shares in Q2 2026, an estimated $77.3K.
  • Vir Biotechnology made up 0.06% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #352 holding.
  • Susquehanna Portfolio Strategies first reported a position in Vir Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.